Search research articles
Contact Us
Filters
Showing results (11-20 of 24) with videos related to
Page
of 3
Sort By:
Biochemical and Biophysical Research Communications
|
January 11, 2011
Enhanced glucose tolerance in the Brattleboro rat
Kazuaki Nakamura, Tatsuya Yamashita, Hiroyuki Fujiki, et al.
Journal of Cardiovascular Pharmacology
|
August 7, 2015
Effects of Long-term Blockade of Vasopressin Receptor Types 1a and 2 on Cardiac and Renal Damage in a Rat Model of Hypertensive Heart Failure
Tomoyuki Ikeda, Yoshitaka Iwanaga, Heitaro Watanabe, et al.
American Journal of Physiology. Renal Physiology
|
August 6, 2011
Tolvaptan inhibits ERK-dependent cell proliferation, Cl⁻ secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin
Gail A Reif, Tamio Yamaguchi, Emily Nivens, et al.
Endocrinology
|
April 16, 2005
Therapeutic effects of tolvaptan, a potent, selective nonpeptide vasopressin V2 receptor antagonist, in rats with acute and chronic severe hyponatremia
Toshiki Miyazaki, Yoshitaka Yamamura, Toshiyuki Onogawa, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
February 27, 2014
Tolvaptan delays the onset of end-stage renal disease in a polycystic kidney disease model by suppressing increases in kidney volume and renal injury
Miki Aihara, Hiroyuki Fujiki, Hiroshi Mizuguchi, et al.
Journal of Pharmacological and Toxicological Methods
|
December 13, 2003
A method for evaluating drug effects on intermittent claudication using a treadmill in rats with unilateral hindlimb artery occlusion
Kensuke Orito, Masami Kishi, Hiroyuki Fujiki, et al.
Circulation. Heart Failure
|
May 26, 2012
Chronic administration of oral vasopressin type 2 receptor antagonist tolvaptan exerts both myocardial and renal protective effects in rats with hypertensive heart failure
Hanako Morooka, Yoshitaka Iwanaga, Yodo Tamaki, et al.
Clinical and Experimental Nephrology
|
December 29, 2014
Exploring urinary biomarkers in autosomal dominant polycystic kidney disease
Haruna Kawano, Satoru Muto, Yasukazu Ohmoto, et al.
Journal of Pharmacological Sciences
|
October 2, 2022
In vitro and in vivo pharmacological profile of OPC-61815, a water-soluble phosphate ester pro-drug of tolvaptan
Hiroyuki Fujiki, Masayuki Matsunaga, Masayuki Furukawa, et al.
Journal of Biomedical Materials Research. Part A
|
September 22, 2009
Artificial cartilage made from a novel double-network hydrogel: In vivo effects on the normal cartilage and ex vivo evaluation of the friction property
Kazunobu Arakaki, Nobuto Kitamura, Hiroyuki Fujiki, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 24) with videos related to
Sort By:
Page
of 3
Biochemical and Biophysical Research Communications
|
January 11, 2011
Enhanced glucose tolerance in the Brattleboro rat
Kazuaki Nakamura, Tatsuya Yamashita, Hiroyuki Fujiki, et al.
Journal of Cardiovascular Pharmacology
|
August 7, 2015
Effects of Long-term Blockade of Vasopressin Receptor Types 1a and 2 on Cardiac and Renal Damage in a Rat Model of Hypertensive Heart Failure
Tomoyuki Ikeda, Yoshitaka Iwanaga, Heitaro Watanabe, et al.
American Journal of Physiology. Renal Physiology
|
August 6, 2011
Tolvaptan inhibits ERK-dependent cell proliferation, Cl⁻ secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin
Gail A Reif, Tamio Yamaguchi, Emily Nivens, et al.
Endocrinology
|
April 16, 2005
Therapeutic effects of tolvaptan, a potent, selective nonpeptide vasopressin V2 receptor antagonist, in rats with acute and chronic severe hyponatremia
Toshiki Miyazaki, Yoshitaka Yamamura, Toshiyuki Onogawa, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
February 27, 2014
Tolvaptan delays the onset of end-stage renal disease in a polycystic kidney disease model by suppressing increases in kidney volume and renal injury
Miki Aihara, Hiroyuki Fujiki, Hiroshi Mizuguchi, et al.
Journal of Pharmacological and Toxicological Methods
|
December 13, 2003
A method for evaluating drug effects on intermittent claudication using a treadmill in rats with unilateral hindlimb artery occlusion
Kensuke Orito, Masami Kishi, Hiroyuki Fujiki, et al.
Circulation. Heart Failure
|
May 26, 2012
Chronic administration of oral vasopressin type 2 receptor antagonist tolvaptan exerts both myocardial and renal protective effects in rats with hypertensive heart failure
Hanako Morooka, Yoshitaka Iwanaga, Yodo Tamaki, et al.
Clinical and Experimental Nephrology
|
December 29, 2014
Exploring urinary biomarkers in autosomal dominant polycystic kidney disease
Haruna Kawano, Satoru Muto, Yasukazu Ohmoto, et al.
Journal of Pharmacological Sciences
|
October 2, 2022
In vitro and in vivo pharmacological profile of OPC-61815, a water-soluble phosphate ester pro-drug of tolvaptan
Hiroyuki Fujiki, Masayuki Matsunaga, Masayuki Furukawa, et al.
Journal of Biomedical Materials Research. Part A
|
September 22, 2009
Artificial cartilage made from a novel double-network hydrogel: In vivo effects on the normal cartilage and ex vivo evaluation of the friction property
Kazunobu Arakaki, Nobuto Kitamura, Hiroyuki Fujiki, et al.
Page
of 3